Progression-free survival (PFS) is often used as surrogate endpoint in clinical trials investigating treatment effectiveness in patients affected by high-risk non-muscle invasive bladder cancer patients (HR-NMIBC). However, the goodness of such surrogate endpoint and its association with overall survival (OS) is challenged by conflicting results showing lack of OS advantage, even in presence of PFS improvement. We aimed to test the effect of time-to-progression on OS in a large cohort of HR-NMIBC treated with intravesical BCG.
MP08-03 PROGRESSION-FREE SURVIVAL AS SURROGATE ENDPOINT IN HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER STUDIES: RESULTS FROM A MACHINE LEARNING-BASED ANALYSIS OF A LARGE MULTI-INSTITUTIONAL DATABASE
Porreca, Annamaria;
2023-01-01
Abstract
Progression-free survival (PFS) is often used as surrogate endpoint in clinical trials investigating treatment effectiveness in patients affected by high-risk non-muscle invasive bladder cancer patients (HR-NMIBC). However, the goodness of such surrogate endpoint and its association with overall survival (OS) is challenged by conflicting results showing lack of OS advantage, even in presence of PFS improvement. We aimed to test the effect of time-to-progression on OS in a large cohort of HR-NMIBC treated with intravesical BCG.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
marchioni-et-al-2023-mp08-03-progression-free-survival-as-surrogate-endpoint-in-high-risk-non-muscle-invasive-bladder.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
48.12 kB
Formato
Adobe PDF
|
48.12 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
